Nascent Biotech Regains Worldwide Rights for Pritumumab

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on pocket
Pocket
Share on whatsapp
WhatsApp
Nascent Biotech Regains Worldwide Rights for Pritumumab

NORTH PALM BEACH, FL / ACCESSWIRE / May 26, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space, announced today that the Company and China based BioRay Pharmaceutical Co have mutually agreed to terminate the license agreement entered into on March 31…
Read More

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on pocket
Pocket
Share on whatsapp
WhatsApp

Never miss any important news. Subscribe to our newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

Receive the latest news

Subscribe To Our Weekly Newsletter

Get notified about new articles